Gustave Roussy Selects TrialMaster EDC to Support Cancer Research

FORT LAUDERDALE, FL., July 05, 2017 (GLOBE NEWSWIRE)-Gustave Roussy, the cancer research institute in Europe, has selected TrialMaster electronic data capture (EDC) technology from OmniComm Systems, Inc., a global provider of clinical data management technology. OmniComm’s TrialMaster will support Gustave Roussy-sponsored clinical trials in oncology that are handled and analyzed by Gustave Roussy’s biostatistics and epidemiology unit. Gustave Roussy focuses on patient care, research, and teaching for all types of cancer.

TrialMaster was chosen because of certain features, including the ability to build studies, adeptness in query management workflow, intuitive interface, monitoring and centralized source review, eLearning modules, exporting abilities, and the range of report types.

“To have an institution as prestigious as Gustave Roussy select TrialMaster is a real testament to the quality, flexibility and scalability of both our EDC technology and our business operations. Moreover, we are incredibly proud to have been selected as their EDC partner,” said Kuno van der Post, OmniComm’s chief commercial officer. “TrialMaster has seen a great deal of well-publicized success over the last 18 months within the academic sector. Coupled with our deployments over that same time period in both pharmacompanies and CROs, it adds up to an achievement that cannot be emulated by many of the EDC systems available today.”

Contact Info

Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KVanderPost@omnicomm.com